Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

Fintel reports that on March 31, 2025, BTIG upgraded their outlook for Progyny (NasdaqGS:PGNY) from Neutral to Buy. Analyst ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

Meeting to be held in Dallas on April 8 hosted by BTIG.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the ...

Jonathan Krinsky, chief market technician at BTIG, sees more slumps for the S&P 500 Index (SPX) forming “W-shape” recoveries, instead of “V-shape” recoveries. The S&P 500 Index (SPX ...

Shares of CrowdStrike (NASDAQ: CRWD) surged higher on Monday. The move up comes as the S&P 500 and Nasdaq Composite had ...

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a ...

BTIG analysts highlighted a historical trend suggesting a potential rebound for the S&P 500 (SPX) in April following a ...

As of March 19, 2025, the average one-year price target for Progyny is $27.71/share. The forecasts range from a low of $23.23 to a high of $35.70. The average price target represents an increase ...